NY-ESO-1 immunotherapy for multiple myeloma

Leukemia and Lymphoma

Volumn 47, Issue 10, 2006, Pages 2037-2048

  Szmania, Susann ^a   Tricot, Guido ^a   van Rhee, Frits ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cancer testis antigen; Myeloma; NY ESO 1; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CANCER VACCINE; CHOLESTEROL; CYTOCHROME P450 1B1; DENDRITIC CELL VACCINE; DIMETHYL SULFOXIDE; DNA VACCINE; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; KEYHOLE LIMPET HEMOCYANIN; MELANOMA ANTIGEN 3; MUCIN 1; NY ESO 1 ANTIGEN; PHOSPHOLIPID; PROTEASOME INHIBITOR; SAPONIN; TELOMERASE REVERSE TRANSCRIPTASE; THALIDOMIDE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOGENETICS; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LUNG CANCER; LYMPHOCYTE TRANSFER; METAPHASE; MULTIPLE MYELOMA; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SARCOMA; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; MULTIPLE MYELOMA; PROGNOSIS;

EID: 33750461287     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600742292     Document Type: Review

References (154)

1. Barlogie, B and jagannath, S and Naucke, S and Mattox, S and Bracy, D and Crowley, J and (1998) Long-term follow-up after high-dose therapy for high-risk multiple myeloma Bone Marrow Transplant, 21, pp. 1101-1107.
2. Barlogie, B and Jagannath, S and Desikan, K and Mattox, S and Vesole, D and Siegel, D and (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood, 93, pp. 55-65.
3. Attal, M and Harousseau, J and Facon, T and Guilhot, F and Doyen, C and Fuzibet, J and (2003) Single versus double autologous stem-cell transplantation for multiple myeloma.[see comment][erratum appears in N Engl J Med 2004;350:2628] N Engl J Med, 349, pp. 2495-2502.
4. Child, J and Morgan, G and Davies, F and Owen, R and Bell, S and Hawkins, K and (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med, 348, pp. 1875-1883.
5. Fassas, A and Shaughnessy, J and Barlogie, B. (2005) Cure of myeloma: hype or reality Bone Marrow Transplant, 35, pp. 215-224.
6. Barlogie, B and Tricot, G and Rasmussen, E and Anaissie, E and van Rhee, F and Zangari, M and (2006) Total therapy 2 wihtout thalidomide: comparison with total therapy 1: Role of intensified induction and post-transplant consolidation therapies Blood, 107, pp. 2633-2638.
7. Barlogie, B and Shaughnessy, J and Tricot, G and Jacobson, J and Zangari, M and Anaissie, E and (2004) Treatment of multiple myeloma Blood, 103, pp. 20-32.
8. Barlogie, B and Tricot, G and Anaissie, E and Shaughnessy, J and Rasmussen, E and van Rhee, F and (2006) Thalidomide and hematopoetic-cell transplantation for multiple myeloma N Engl J Med, 354, pp. 1021-1030.
9. Tricot, G and Vesole, D and Jagannath, S and Hilton, J and Munshi, N and Barlogie, B. (1996) Graft-versus-myeloma effect: Proof of principle Blood, 87, pp. 1196-1198.
10. Badros, A and Barlogie, B and Morris, C and Desikan, R and Martin, S and Munshi, N and (2001) High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions Blood, 97, pp. 2574-2579.
11. Mohty, M and Boiron, J and Damaj, G and Michallet, A and Bay, J and Faucher, C and (2004) Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation Bone Marrow Transplant, 34, pp. 77-84.
12. Lokhorst, H and Schattenberg, A and Cornelissen, J and van Oers, M and Fibbe, W and Russell, I and (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome J Clin Oncol, 18, pp. 3031-3037.
13. Davis, I and Chen, W and Jackson, H and Parente, P and Shackleton, M and Hopkins, W and (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans Proc Natl Acad Sci (USA), 101, pp. 10697-10702.
14. Jager, E. (2005) Vaccine strategies against NY-ESO-1 in cancer patients Cancer Imm, 5, pp. 12.
15. Davis, I and Schnurr, M and Hopkins, W and Miloradovic, L and Old, L and (2005) NY-ESO-1 protein-based cancer vaccines: The Melbourne experience Cancer Imm, 5, pp. 13.
16. Dudley, M and Wunderlich, J and Yang, J and Sherry, R and Topalian, S and Restifo, N and (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol, 23, pp. 2346-2357.
17. Ratta, M and Curti, A and Fogli, M and Pantucci, M and Viscomi, G and Tazzari, P and (2000) Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients Exp Hematol, 28, pp. 931-940.
18. Yi, Q and Desikan, K and Barlogie, B and Munshi, N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma Br J Haematol, 117, pp. 297-305.
19. Bendandi, M and Gocke, C and Kobrin, C and Benko, F and Sternas, L and Pennington, R and (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma Nat Med, 5, pp. 1171-1177.
20. Neelapu, S and Baskar, S and Kwak, L. (2001) Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine J Cancer Res Clin Oncol, 127(2), pp. R14-R19.
21. Timmerman, J and Czerwinski, D and Davis, T and Hsu, F and Benike, C and Hao, Z and (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients Blood, 99, pp. 1517-1526.
22. Coscia, M and Mariani, S and Battaglio, S and Di Bello, C and Fiore, F and Foglietta, M and (2004) Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy Leukemia, 18, pp. 139-145.
23. Stevenson, F and Ottensmeier, C and Johnson, P and Zhu, D and Buchan, S and McCann, K and (2004) DNA vaccines to attack cancer Proc Natl Acad Sci (USA), 101(Suppl 2), pp. 14646-14652.
24. Sahota, S and Townsend, M and Stevenson, F. (2005) Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma Meth Mol Med, 113, pp. 105-119.
25. Timmerman, J and Levy, R. (2000) Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine J Immunol, 164, pp. 4797-4803.
26. Liso, A and Stockerl-Goldstein, K and Auffermann-Gretzinger, S and Benike, C and Reichardt, V and van Beckhoven, A and (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma Biol Blood Marrow Transplant, 6, pp. 621-627.
27. Reichardt, V and Milazzo, C and Brugger, W and Einsele, H and Kanz, L and Brossart, P. (2003) Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells Haematologica, 88, pp. 1139-1149.
28. Reichardt, V and Okada, C and Liso, A and Benike, C and Stockerl-Goldstein, K and Engleman, E and (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study Blood, 93, pp. 2411-2419.
29. Bogen, B. (1996) Peripheral T cell tolerance as a tumor escape mechanism: Deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma Eur J Immunol, 26, pp. 2671-2679.
30. Treon, S and Maimonis, P and Bua, D and Young, G and Raje, N and Mollick, J and (2000) Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma Blood, 96, pp. 3147-3153.
31. Neelapu, S and Munshi, N and Jagannath, S and Watson, T and Pennington, R and Reynolds, C and (2005) Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma Bone Marrow Transplant, 36, pp. 315-323.
32. Bendandi, M and Rodriguez-Cavillo, M and Inoges, S and de Cerio, A and Perez-Simon, J and Rodriguez-Cabellero, A. (2006) Combined vaccination with idiotype-pulsed dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation Leuk Lymphoma, 47, pp. 29-37.
33. Szmania, S and Cottler-Fox, M and Rosen, N and Viswamitra, S and Moreno, A and Pomtree, M and (2004) A novel strategy for combining immunotherapy with high dose chemotherapy and auto-transplantation in high risk multiple myeloma Blood, 104, pp. 798a. Abstract # 2920
34. Borello, I and Biedrzycki, B and Sheets, N and Racke, F and Huff, C and Loper, K and (2003) Autologous tumor combined with a GM-CSF-secreting cell line vaccine following autologous stem cell transplant (ASCT) in multiple myeloma Proc Am Soc Clin Ocol, 22, pp. 167.
35. Raje, N and Hideshima, T and Davies, F and Chauhan, D and Treon, S and Young, G and (2004) Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma Br J Haematol, 125, pp. 343-352.
36. Hao, S and Chan, T and Xiang, J. (2005) Genetically engineered myeloma cell vaccine Meth Mol Med, 113, pp. 235-244.
37. Xia, D and Chan, T and Xiang, J. (2005) Dendritic cell/myeloma hybrid vaccine Meth Mol Med, 113, pp. 225-233.
38. Treon, S and Shima, Y and Grossbard, M and Preffer, F and Belch, A and Pilarski, L and (2000) Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens Ann Oncol, 11, pp. 107-111.
39. Goto, T and Kennel, S and Abe, M and Takishita, M and Kosaka, M and Solomon, A and (1994) A novel membrane antigen selectively expressed on terminally differentiated human B cells Blood, 84, pp. 1922-1930.
40. Ohtomo, T and Sugamata, Y and Ozaki, Y and Ono, K and Yoshimura, Y and Kawai, S and (1999) Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells Biochem Biophys Res Comm, 258, pp. 583-591.
41. Lim, S and Wang, Z and Chiriva-Internati, M and Xue, Y. (2001) Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma Blood, 97, pp. 1508-1510.
42. Zhang, Y and Wang, Z and Robinson, W and Lim, S. (2004) Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen Eur J Haematol, 73, pp. 280-284.
43. Maecker, B and Sherr, D and Vonderheide, R and von Bergwelt-Baildon, M and Hirano, N and Anderson, K and (2003) The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells Blood, 102, pp. 3287-3294.
44. Wu, K and Grandori, C and Amacker, M and Simon-Vermot, N and Polack, A and Lingner, J and (1999) Direct activation of TERT transcription by c-MYC Nat Genet, 21, pp. 220-224.
45. Qian, J and Wang, S and Yang, J and Xie, J and Lin, P and Freeman, M, 3 and (2005) Targeting heat shock proteins for immunotherapy in multiple myeloma: Generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96 Clin Cancer Res, 11, pp. 8808-8815.
46. Brugger, W and Buhring, H and Grunebach, F and Vogel, W and Kaul, S and Muller, R and (1999) Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells J Clin Oncol, 17, pp. 1535-1544.
47. Grizzi, F and Chiriva-Internati, M and Franceschini, B and Bumm, K and Colombo, P and Ciccarelli, M and (2004) Sperm protein 17 is expressed in human somatic ciliated epithelia J Histochem Cytochem, 52, pp. 549-554.
48. Dadabayev, A and Wang, Z and Zhang, Y and Zhang, J and Robinson, W and Lim, S. (2005) Cancer immunotherapy targeting Sp17: When should the laboratory findings be translated to the clinics Am J Hematol, 80, pp. 6-11.
49. Brossart, P and Schneider, A and Dill, P and Schammann, T and Grunebach, F and Wirths, S and (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes Cancer Res, 61, pp. 6846-6850.
50. Chiriva-Internati, M and Wang, Z and Xue, Y and Bumm, K and Hahn, A and Lim, S. (2001) Sperm protein 17 (Sp17) in multiple myeloma: Opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk Eur J Immunol, 31, pp. 2277-2283.
51. Rew, S and Peggs, K and Sanjuan, I and Pizzey, A and Koishihara, Y and Kawai, S and (2005) Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24 Clin Cancer Res, 11, pp. 3377-3384.
52. Maecker, B and von Bergwelt-Baildon, M and Anderson, K and Vonderheide, R and Anderson, K and Nadler, L and (2005) Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients Clin Exp Immunol, 141, pp. 558-562.
53. Gribben, J and Ryan, D and Boyajian, R and Urban, R and Hedley, M and Beach, K and (2005) Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy Clin Cancer Res, 11, pp. 4430-4436.
54. Reddish, M and MacLean, G and Koganty, R and Kan-Mitchell, J and Jones, V and Mitchell, M and (1998) Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide Int J Cancer, 76, pp. 817-823.
55. Jungbluth, A and Ely, S and DiLiberto, M and Niesvizky, R and Williamson, B and Frosina, D and (2005) The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation Blood, 106, pp. 167-174.
56. Dhodapkar, M and Osman, K and Teruya-Feldstein, J and Filippa, D and Hedvat, C and Iversen, K and (2003) Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease Cancer Imm, 3, pp. 9.
57. Taylor, B and Reiman, T and Pittman, J and Keats, J and de Bruin, D and Mant, M and (2005) SSX cancer testis antigens are expressed in most multiple myeloma patients J Immunother, 28, pp. 564-575.
58. Szmania, S and Bennett, G and Batchu, R and Rosen, N and Gupta, S and Xie, J and (2002) Dendritic cells pulsed with NY-ESO-1 and MAGE-3 peptides stimulate myeloma specific cytotoxic T lymphocytes Blood, 100, pp. 399a.
59. Chen, Y and Scanlan, M and Sahin, U and Tureci, O and Gure, A and Tsang, S and (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening Proc Natl Acad Sci (USA), 94, pp. 1914-1918.
60. Lethe, B and Lucas, S and Michaux, L and De Smet, C and Godelaine, D and Serrano, A and (1998) LAGE-1, a new gene with tumor specificity Int J Cancer, 76, pp. 903-908.
61. Alpen, B and Gure, A and Scanlan, M and Old, L and Chen, Y. (2002) A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved Gene, 297, pp. 141-149.
62. Scanlan, M and Simpson, A and Old, L. (2004) The cancer/testis genes: review, standardization, and commentary Cancer Imm, 4, pp. 1.
63. Chen, Y and Boyer, A and Viars, C and Tsang, S and Old, L and Arden, K. (1997) Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28 Cytogen Cell Gen, 79, pp. 237-240.
64. Zendman, A and Ruiter, D and van Muijen, G. (2003) Cancer/ testis-associated genes: Identification, expression profile, and putative function J Cell Physiol, 194, pp. 272-288.
65. Jungbluth, A and Chen, Y and Stockert, E and Busam, K and Kolb, D and Iversen, K and (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues Int J Cancer, 92, pp. 856-860.
66. Sugita, Y and Wada, H and Fujita, S and Nakata, T and Sato, S and Noguchi, Y and (2004) NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors Cancer Res, 64, pp. 2199-2204.
67. Nakada, T and Noguchi, Y and Satoh, S and Ono, T and Saika, T and Kurashige, T and (2003) NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer Cancer Imm, 3, pp. 10.
68. Fujita, S and Wada, H and Jungbluth, A and Sato, S and Nakata, T and Noguchi, Y and (2004) NY-ESO-1 expression and immunogenicity in esophageal cancer Clin Cancer Res, 10, pp. 6551-6558.
69. Sarcevic, B and Spagnoli, G and Terracciano, L and Schultz-Thater, E and Heberer, M and Gamulin, M and (2003) Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma Oncology, 64, pp. 443-449.
70. Kienstra, M and Neel, H and Strome, S and Roche, P. (2003) Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma Head Neck, 25, pp. 457-463.
71. Akcakanat, A and Kanda, T and Tanabe, T and Komukai, S and Yajima, K and Nakagawa, S and (2006) Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy Int J Cancer, 118, pp. 123-128.
72. Odunsi, K and Jungbluth, A and Stockert, E and Qian, F and Gnjatic, S and Tammela, J and (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer Cancer Res, 63, pp. 6076-6083.
73. Maio, M and Coral, S and Sigalotti, L and Elisei, R and Romei, C and Rossi, G and (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: Expression and humoral response to NY-ESO-1 J Clin Endocrinol Metab, 88, pp. 748-754.
74. Schultz-Thater, E and Noppen, C and Gudat, F and Durmuller, U and Zajac, P and Kocher, T and (2000) NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens Br J Cancer, 83, pp. 204-208.
75. Sharma, P and Gnjatic, S and Jungbluth, A and Williamson, B and Herr, H and Stockert, E and (2003) Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer Cancer Immun, 3, pp. 19.
76. Wang, Y and Wu, X and Zhao, A and Yuan, Y and Chen, Y and Jungbluth, A and (2004) Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer Cancer Immun, 4, pp. 11.
77. Mischo, A and Kubuschok, B and Ertan, K and Preuss, K and Romeike, B and Regitz, E and (2006) Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer Int J Cancer, 118, pp. 696-703.
78. Kurashige, T and Noguchi, Y and Saika, T and Ono, T and Nagata, Y and Jungbluth, A and (2001) NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade Cancer Res, 61, pp. 4671-4674.
79. van Rhee, F and Szmania, S and Zhan, F and Gupta, S and Pomtree, M and Lin, P and (2005) NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses Blood, 105, pp. 3939-3944.
80. van Baren, N and Brasseur, F and Godelaine, D and Hames, G and Ferrant, A and Lehmann, F and (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells Blood, 94, pp. 1156-1164.
81. Pellat-Deceunynck, C. (2003) Tumour-associated antigens in multiple myeloma Br J Haematol, 120, pp. 3-9.
82. de Vos, J and Thykjaer, T and Tarte, K and Ensslen, M and Raynaud, P and Requirand, G and (2002) Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays Oncogene, 21, pp. 6848-6857.
83. Zhan, F and Hardin, J and Kordsmeier, B and Bumm, K and Zheng, M and Tian, E and (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Blood, 99, pp. 1745-1757.
84. Hong, J and Kang, Y and Abdullaev, Z and Flanagan, P and Pack, S and Fischette, M and (2005) Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells Cancer Res, 65, pp. 7763-7774.
85. De Smet, C and Lurquin, C and Lethe, B and Martelange, V and Boon, T. (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter Mol Cell Biol, 19, pp. 7327-7335.
86. Tarte, K and de Vos, J and Thykjaer, T and Zhan, F and Fiol, G and Costes, V and (2002) Generation of polyclonal plasmablasts from peripheral blood B cells: A normal counterpart of malignant plasmablasts [see comment] Blood, 100, pp. 1113-1122.
87. Pellat-Deceunynck, C and Mellerin, M and Labarriere, N and Jego, G and Moreau-Aubry, A and Harousseau, J and (2000) The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells Eur J Immunol, 30, pp. 803-809.
88. Gure, A and Chua, R and Williamson, B and Gonen, M and Ferrera, C and Gnjatic, S and (2005) Cancer-Testis genes are coordinately expressed and are markers of poor aoutcome in non-small cell lung cancer Clin Cancer Res, 11, pp. 8055-8062.
89. Harrison, S and Cook, G. (2005) Immunotherapy in multiple myeloma - possibility or probability Br J Haematol, 130, pp. 344-362.
90. Jager, E and Chen, Y and Drijfhout, J and Karbach, J and Ringhoffer, M and Jager, D and (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes J Exp Med, 187, pp. 265-270.
91. Valmori, D and Dutoit, V and Lienard, D and Rimoldi, D and Pittet, M and Champagne, P and (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients Cancer Res, 60, pp. 4499-4506.
92. Stockert, E and Jager, E and Chen, Y and Scanlan, M and Gout, I and Karbach, J and (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens [comment] J Exp Med, 187, pp. 1349-1354.
93. Jager, E and Nagata, Y and Gnjatic, S and Wada, H and Stockert, E and Karbach, J and (2000) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses Proc Natl Acad Sci (USA), 97, pp. 4760-4765.
94. Jager, E and Gnjatic, S and Nagata, Y and Stockert, E and Jager, D and Karbach, J and (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers Proc Natl Acad Sci (USA), 97, pp. 12198-12203.
95. Zeng, G and Wang, X and Robbins, P and Rosenberg, S and Wang, R. (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production Proc Natl Acad Sci (USA), 98, pp. 3964-3969.
96. Khong, H and Rosenberg, S. (2002) Pre-existing immunity to tyrosinase-related protein (TRP)- 2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy J Immunol, 168, pp. 951-956.
97. Qian, F and Gnjatic, S and Jager, E and Santiago, D and Jungbluth, A and Grande, C and (2004) Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer Cancer Immun, 4, pp. 12.
98. Huarte, E and Karbach, J and Gnjatic, S and Bender, A and Jager, D and Arand, M and (2004) HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones Cancer Immun, 4, pp. 15.
99. Gnjatic, S and Nagata, Y and Jager, E and Stockert, E and Shankara, S and Roberts, B and (2000) Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele Proc Natl Acad Sci (USA), 97, pp. 10917-10922.
100. Goodyear, O and Piper, K and Khan, N and Starczynski, J and Mahendra, P and Pratt, G and (2005) CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden Blood, 106, pp. 4217-4224.
101. Hoeppner, L and Dubovsky, J and Dunphy, E and McNeel, D. (2006) Humoral immune responses to testits antigens in sera from patients with prostate cancer Cancer Immun, 6, pp. 1-7.
102. Gnjatic, S and Jager, E and Chen, W and Altorki, N and Matsuo, M and Lee, S and (2002) CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients Proc Natl Acad Sci (USA), 99, pp. 11813-11818.
103. Chen, Q and Jackson, H and Parente, P and Luke, T and Rizkalla, M and Tai, T and (2004) Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant Proc Natl Acad Sci (USA), 101, pp. 9363-9368.
104. Riker, A and Kammula, U and Panelli, M and Wang, E and Ohnmacht, G and Steinberg, S and (2000) Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes Int J Cancer, 86, pp. 818-826.
105. Marincola, F and Jaffee, E and Hicklin, D and Ferrone, S. (2000) Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance Adv Immunol, 74, pp. 181-273.
106. Hung, K and Hayashi, R and Lafond-Walker, A and Lowenstein, C and Pardoll, D and Levitsky, H. (1998) The central role of CD4(+) T cells in the antitumor immune response J Exp Med, 188, pp. 2357-2368.
107. Pardoll, D and Topalian, S. (1998) The role of CD4+ T cell responses in antitumor immunity Curr Opin Immunol, 10, pp. 588-594.
108. Toes, R and Ossendorp, F and Offringa, R and Melief, C. (1999) CD4 T cells and their role in antitumor immune responses J Exp Med, 189, pp. 753-756.
109. Valmori, D and Souleimanian, N and Hesdorffer, C and Ritter, G and Old, L and Ayyoub, M. (2005) Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses Clin Immunol, 117, pp. 24-30.
110. Preuss, K and Regitz, E and Neumann, F and Pfreundschuh, M. (2006) B-cell epitopes from the cancer testis antigen NY-ESO-1 Int J Cancer, 118, pp. 253.
111. Zeng, G and Aldridge, M and Wang, Y and Pantuck, A and Wang, A and Liu, Y and (2005) Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker [see comment] Int J Cancer, 114, pp. 268-273.
112. Rammensee, H and Bachmann, J and Emmerich, N and Bachor, O and Stevanovic, S. (1999) SYFPEITHI: Database for MHC ligands and peptide motifs Immunogenetics, 50, pp. 213-219.
113. Parker, K and Bednarek, M and Coligan, J. (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J Immunol, 152, pp. 163-175.
114. Dutoit, V and Taub, R and Papadopoulos, K and Talbot, S and Keohan, M and Brehm, M and (2002) Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting [comment] J Clin Invest, 110, pp. 1813-1822.
115. Bownds, S and Tong-On, P and Rosenberg, S and Parkhurst, M. (2001) Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution J Immunother, 24, pp. 1-9.
116. Chen, J and Dunbar, P and Gileadi, U and Jager, E and Gnjatic, S and Nagata, Y and (2000) Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL J Immunol, 165, pp. 948-955.
117. Le Gal, F and Ayyoub, M and Dutoit, V and Widmer, V and Jager, E and Cerottini, J and (2005) Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1 J Immunother, 28, pp. 252-257.
118. Khong, H and Yang, J and Topalian, S and Sherry, R and Mavroukakis, S and White, D and (2004) Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen J Immunother, 27, pp. 472-477.
119. Khong, H and Wang, Q and Rosenberg, S. (2004) Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression J Immunother, 27, pp. 184-190.
120. Zeng, G and Li, Y and El-Gamil, M and Sidney, J and Sette, A and Wang, R and (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: A new strategy for vaccine design Cancer Res, 62, pp. 3630-3635.
121. Celis, E. (2002) Getting peptide vaccines to work: Just a matter of quality control? [see comment] J Clin Invest, 110, pp. 1765-1768.
122. Murphy, R and Green, S and Ritter, G and Cohen, L and Ryan, D and Woods, W and (2005) Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions Prep Biochem Biotechnol, 35, pp. 119-134.
123. Batchu, R and Moreno, A and Szmania, S and Bennett, G and Spagnoli, G and Ponnazhagan, S and (2005) Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma Cancer Res, 65, pp. 10041-10049.
124. Gnjatic, S and Szmania, S and Moreno, A and Cottler-Fox, M and Shaughnessy, J and Barlogie, B and (2005) Vaccination with MAGE-3 protein can induce a potent immune response in a healthy donor which can be adoptively transferred via stem cell transplant to a multiple myeloma patient Blood, 106, pp. 620a.
125. Ennis, F and Cruz, J and Jameson, J and Klein, M and Burt, D and Thipphawong, J. (1999) Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS) Virology, 259, pp. 256-261.
126. Batchu, R and Moreno, A and Szmania, S and Gupta, S and Zhan, F and Rosen, N and (2003) High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector Human Gene Ther, 14, pp. 1333-1345.
127. Lopex, L and Fletcher, K and Ikeda, Y and Collins, M. (2005) Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy Cancer Immunol Immunother, 26, pp. 1-6.
128. Dhodapkar, K and Krasovsky, J and Williamson, B and Dhodapkar, M. (2002) Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells [comment] J Exp Med, 195, pp. 125-133.
129. Nagata, Y and Matsuo, M and Gnjatic, S and Valmori, D and Ritter, G and Garrett, W and (2002) Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations PNAS, 99, pp. 10629-10634.
130. Cioca, D and Deak, E and Cioca, F and Paunescu, V. (2006) Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently corss-prime CD8+ T cells J Immunother, 29, pp. 41-52.
131. Chen, W and Jackson, H and Dimopoulos, N and Tai, T and Mifsud, N and Chen, Q and (2005) Systematic analysis of anti-NY-ESO-1 T cell responses reveals striking HLA-dependant immunodominance J Immunother, 28, pp. 629.
132. Smith, C and Mirza, F and Pasquetto, V and Tscharke, D and Palmowski, M and Dunbar, P and (2005) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara J Immunol, 175, pp. 8431-8437.
133. Rosenberg, S and Yang, J and Restifo, N. (2004) Cancer immunotherapy: moving beyond current vaccines [see comment] Nature Med, 10, pp. 909-915.
134. Dudley, M and Wunderlich, J and Robbins, P and Yang, J and Hwu, P and Schwartzentruber, D and (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science, 298, pp. 850-854.
135. Rosenberg, S. (2004) Shedding light on immunotherapy for cancer N Engl J Med, 350, pp. 1461-1463.
136. Coulie, P and Connerotte, T. (2005) Human tumor-specific T lymphocytes: does function matter more than number Curr Opin Immunol, 17, pp. 320-325.
137. Xue, S and Gao, L and Hart, D and Gillmore, R and Qasim, W and Thrasher, A and (2005) Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells Blood, 106, pp. 3062-3067.
138. Zhao, Y and Zheng, Z and Robbins, P and Khong, H and Rosenberg, S and Morgan, R. (2005) Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines J Immunol, 174, pp. 4415-4423.
139. Brown, R and Pope, B and Murray, A and Esdale, W and Sze, D and Gibson, J and (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10 Blood, 98, pp. 2992-2998.
140. Letterio, J and Roberts, A. (1997) TGF-beta: A critical modulator of immune cell function Clin Immunol Immunopathol, 84, pp. 244-250.
141. Powell, D, Jr and Parker, L and Rosenberg, S. (2005) Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples J Immunother, 28, pp. 403-411.
142. Shi, J and Szmania, S and Rosen, N and Moreno, A and Walker, R and Dupont, B and (2005) Killer immunoglobulin-like receptor ligand mismatched natural killer cell transfusions for multiple myeloma Blood, 106, pp. 969a.
143. Jager, E and Ringhoffer, M and Karbach, J and Arand, M and Oesch, F and Knuth, A. (1996) Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo Int J Cancer, 66, pp. 470-476.
144. Gattei, V and Fonsatti, E and Sigalotti, L and Degan, M and Di Giacomo, A and Altomonte, M and (2005) Epigenetic immunomodulation of hematopoietic malignancies Sem Oncol, 32, pp. 503-510.
145. Egger, G and Liang, G and Aparicio, A and Jones, P. (2004) Epigenetics in human disease and prospects for epigenetic therapy Nature, 429, pp. 457-463.
146. Weiser, T and Guo, Z and Ohnmacht, G and Parkhurst, M and Tong-On, P and Marincola, F and (2001) Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY- ESO-1 J Immunother, 24, pp. 151-161.
147. Lurquin, C and Lethe, B and De Plaen, E and Corbiere, V and Theate, I and van Baren, N and (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen J Exp Med, 201, pp. 249-257.
148. Tohnya, T and Figg, W. (2004) Immunomodulation of multiple myeloma Cancer Biol Ther, 3, pp. 1060-1061.
149. Davies, F and Raje, N and Hideshima, T and Lentzsch, S and Young, G and Tai, Y and (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [see comment] Blood, 98, pp. 210-216.
150. Szmania, S and Yi, Q and Cottler-Fox, M and Rosen, N and Freeman, J and Kordsmeier, B and (2005) Clinical-grade myeloma ag pre-loaded DC vaccines retain potency after cryopreservation Cytotherapy, 7, pp. 374-384.
151. Chen, Q and Jackson, H and Shackleton, M and Parente, P and Hopkins, W and Sturrock, S and (2005) Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination Cancer Immun, 5, pp. 5.
152. Shackleton, M and Davis, I and Hopkins, W and Jackson, H and Dimopoulos, N and Tai, T and (2004) The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand Cancer Immun, 4, pp. 9.
153. Sharma, P and Bajorin, D and Altorki, N and Hiroyoshi, N and Old, L and Gnjatic, S. (2005) Protein and DNA based vaccines with the NY-ESO-1 antigen in cancer patients J Immunother, 28, pp. 659.
154. Zarour, H and Andrade, P and Mandic, M and Kudela, P and Janjic, B and Land, S and (2005) Randomized phaseI/II study of vaccination with CpG 7909, montanide ISA 720 and NY-ESO-1 peptides for patients with stage III/IV melanoma and NY-ESO-1 positive tumors: An interim analysis J Immunother, 28, pp. 661.